157 related articles for article (PubMed ID: 7849310)
1. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia.
Walters MC; Sullivan KM; Bernaudin F; Souillet G; Vannier JP; Johnson FL; Lenarsky C; Powars D; Bunin N; Ohene-Frempong K
Blood; 1995 Feb; 85(4):879-84. PubMed ID: 7849310
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow transplantation for sickle cell disease.
Walters MC; Patience M; Leisenring W; Eckman JR; Scott JP; Mentzer WC; Davies SC; Ohene-Frempong K; Bernaudin F; Matthews DC; Storb R; Sullivan KM
N Engl J Med; 1996 Aug; 335(6):369-76. PubMed ID: 8663884
[TBL] [Abstract][Full Text] [Related]
3. Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant.
Maheshwari S; Kassim A; Yeh RF; Domm J; Calder C; Evans M; Manes B; Bruce K; Brown V; Ho R; Frangoul H; Yang E
Bone Marrow Transplant; 2014 Mar; 49(3):366-9. PubMed ID: 24317124
[TBL] [Abstract][Full Text] [Related]
4. Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions.
Walters MC; Patience M; Leisenring W; Rogers ZR; Dinndorf P; Davies SC; Roberts IA; Yeager A; Kurtzberg J; Bunin N; Scott JP; Wall DA; Wayne AS; Wiley J; Darbyshire PJ; Mentzer WC; Smith FO; Sullivan KM
Biol Blood Marrow Transplant; 1997 Dec; 3(6):310-5. PubMed ID: 9502298
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow transplantation for sickle cell disease. The United States experience.
Johnson FL; Mentzer WC; Kalinyak KA; Sullivan KM; Abboud MR
Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):22-6. PubMed ID: 8311168
[TBL] [Abstract][Full Text] [Related]
6. Treosulfan, cyclophosphamide and antithymocyte globulin for allogeneic hematopoietic cell transplantation in acquired severe aplastic anemia.
Giebel S; Wojnar J; Krawczyk-Kulis M; Markiewicz M; Wylezoł I; Seweryn M; Holowiecka-Goral A; Holowiecki J
Ann Transplant; 2006; 11(2):23-7; discussion 32-43. PubMed ID: 17494286
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
[TBL] [Abstract][Full Text] [Related]
8. Neurologic complications after bone marrow transplantation for sickle cell anemia.
Ferster A; Christophe C; Dan B; Devalck C; Sariban E
Blood; 1995 Jul; 86(1):408-9. PubMed ID: 7795250
[No Abstract] [Full Text] [Related]
9. Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.
Maschan AA; Trakhtman PE; Balashov DN; Shipicina IP; Skorobogatova EV; Skvortsova YV; Dyshlevaja ZM; Samochatova EV; Rumiantsev AG
Bone Marrow Transplant; 2004 Aug; 34(4):305-7. PubMed ID: 15195080
[TBL] [Abstract][Full Text] [Related]
10. Stem cell transplantation for sickle cell disease: can we reduce the toxicity?
Fixler J; Vichinsky E; Walters MC
Pediatr Pathol Mol Med; 2001; 20(1):73-86. PubMed ID: 12673845
[TBL] [Abstract][Full Text] [Related]
11. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
Eapen M; Brazauskas R; Walters MC; Bernaudin F; Bo-Subait K; Fitzhugh CD; Hankins JS; Kanter J; Meerpohl JJ; Bolaños-Meade J; Panepinto JA; Rondelli D; Shenoy S; Williamson J; Woolford TL; Gluckman E; Wagner JE; Tisdale JF
Lancet Haematol; 2019 Nov; 6(11):e585-e596. PubMed ID: 31495699
[TBL] [Abstract][Full Text] [Related]
12. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease.
Walters MC; Storb R; Patience M; Leisenring W; Taylor T; Sanders JE; Buchanan GE; Rogers ZR; Dinndorf P; Davies SC; Roberts IA; Dickerhoff R; Yeager AM; Hsu L; Kurtzberg J; Ohene-Frempong K; Bunin N; Bernaudin F; Wong WY; Scott JP; Margolis D; Vichinsky E; Wall DA; Wayne AS; Pegelow C; Redding-Lallinger R; Wiley J; Klemperer M; Mentzer WC; Smith FO; Sullivan KM
Blood; 2000 Mar; 95(6):1918-24. PubMed ID: 10706855
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow transplantation for patients with acquired severe aplastic anemia using cyclophosphamide and antithymocyte globulin: the experience from a single center.
Abdelkefi A; Ben Othman T; Ladeb S; Torjman L; Hsaïri M; Ben Abdeladhim A
Hematol J; 2003; 4(3):208-13. PubMed ID: 12764353
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine-associated seizures in bone marrow transplant recipients given busulfan and cyclophosphamide preparative therapy.
Ghany AM; Tutschka PJ; McGhee RB; Avalos BR; Cunningham I; Kapoor N; Copelan EA
Transplantation; 1991 Aug; 52(2):310-5. PubMed ID: 1871805
[TBL] [Abstract][Full Text] [Related]
15. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin.
Storb R; Weiden PL; Sullivan KM; Appelbaum FR; Beatty P; Buckner CD; Clift RA; Doney KC; Hansen J; Martin PJ
Blood; 1987 Jul; 70(1):116-21. PubMed ID: 3297199
[TBL] [Abstract][Full Text] [Related]
16. Barriers to bone marrow transplantation for sickle cell anemia.
Walters MC; Patience M; Leisenring W; Eckman JR; Buchanan GR; Rogers ZR; Olivieri NE; Vichinsky E; Davies SC; Mentzer WC; Powars D; Scott JP; Bernaudin F; Ohene-Frempong K; Darbyshire PJ; Wayne A; Roberts IA; Dinndorf P; Brandalise S; Sanders JE; Matthews DC; Appelbaum FR; Storb R; Sullivan KM
Biol Blood Marrow Transplant; 1996 May; 2(2):100-4. PubMed ID: 9118298
[TBL] [Abstract][Full Text] [Related]
17. Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative.
de la Fuente J; Dhedin N; Koyama T; Bernaudin F; Kuentz M; Karnik L; Socié G; Culos KA; Brodsky RA; DeBaun MR; Kassim AA
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1197-1209. PubMed ID: 30500440
[TBL] [Abstract][Full Text] [Related]
18. Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial.
Horan JT; Haight A; Dioguardi JL; Brown C; Grizzle A; Shelman C; Kanter J; Hale G; Nieder M; Benton M; Kasow KA; Abraham A; Chiang KY
Biol Blood Marrow Transplant; 2015 May; 21(5):900-5. PubMed ID: 25617808
[TBL] [Abstract][Full Text] [Related]
19. HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease.
Pawlowska AB; Cheng JC; Karras NA; Sun W; Wang LD; Bell AD; Gutierrez L; Rosenthal J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):185-189. PubMed ID: 28939451
[TBL] [Abstract][Full Text] [Related]
20. Neurologic complications following bone marrow transplantation for sickle cell disease.
Abboud MR; Jackson SM; Barredo J; Holden KR; Cure J; Laver J
Bone Marrow Transplant; 1996 Mar; 17(3):405-7. PubMed ID: 8704695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
